Viome buys Solarea Bio to push into consumer synbiotics
What's the deal? Viome has acquired Solarea Bio, aiming to launch clinically validated consumer synbiotics and medical foods. Terms were undisclosed. The deal was announced in October 2026.
What's the endgame? The acquisition folds Solarea Bio's technology into Viome's portfolio, extending its reach into medical foods alongside consumer products.
Why now? The move lands amid wider consolidation in agrifood and biotech, as companies combine capabilities to bring science-backed health products to market faster.
The signal: Dealmaking across the sector is picking up, from Greenforce's purchase of NeggstDealroom has a profile for this one. Try Dealroom →'s plant-based egg tech to this acquisition — a sign that firms are buying growth and technology rather than building it alone.
Read more: agfundernews.com
Image credit: IBM Research
